Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.

  • David Minarik
  • Katarina Sjögreen Gleisner
  • Ola Lindén
  • Karin Wingårdh
  • Jan Tennvall
  • Sven-Erik Strand
  • Michael Ljungberg
Publishing year: 2010
Language: English
Pages: 1974-1978
Publication/Series: Journal of Nuclear Medicine
Volume: 51
Issue: 12
Document type: Journal article
Publisher: Society of Nuclear Medicine

Abstract english

This feasibility study demonstrates (90)Y quantitative bremsstrahlung imaging of patients undergoing high-dose myeloablative (90)Y-ibritumomab treatment. METHODS: The study includes pretherapy (111)In SPECT/CT and planar whole-body (WB) imaging at 7 d and therapy (90)Y SPECT/CT at 6 d and (90)Y WB imaging at 1 d. Time-activity curves and organ-absorbed doses derived from (90)Y SPECT images were compared with pretherapy (111)In estimates. Organ activities derived from (90)Y WB images at the first day were compared with corresponding pretherapy estimates. RESULTS: Pretherapy (111)In images from 3 patients were similar to the (90)Y images. Differences between absorbed-dose estimates from pretherapy (111)In and (90)Y therapy were within 25%, except for the lungs. Corresponding activity differences derived from WB images were within 25%. Differences were ascribed to incomplete compensation methods and real differences in pharmacokinetics between pretherapy and therapy. CONCLUSION: Quantitative bremsstrahlung imaging to estimate organ activities and absorbed doses is feasible.


  • Radiology, Nuclear Medicine and Medical Imaging
  • quantification
  • activity
  • radioimmunotherapy
  • imaging
  • yttrium
  • bremsstrahlung


  • ISSN: 0161-5505
Sven-Erik Strand
E-mail: sven-erik [dot] strand [at] med [dot] lu [dot] se

Project manager

Systemic Radiation Therapy Group


Professor emeritus

Medical Radiation Physics, Lund